AnaptysBio, Inc.

NasdaqGS:ANAB 株式レポート

時価総額:US$654.7m

AnaptysBio 過去の業績

過去 基準チェック /06

AnaptysBioの収益は年間平均-23%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間19% 5.6%割合で 減少しています。

主要情報

-23.0%

収益成長率

-22.8%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率-5.6%
株主資本利益率-1,722.0%
ネット・マージン-558.2%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs

Nov 01

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Aug 15

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

Jul 08

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 22
News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22
Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24
AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27
Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Oct 05

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Sep 14
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Sep 12

AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

Sep 01
AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%

Aug 31

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

Aug 08

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

May 10
Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Mar 16
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

Nov 11
AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business

Jul 28
AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business

Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 09
Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

AnaptysBio EPS beats by $0.03, beats on revenue

May 04

収支内訳

AnaptysBio の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:ANAB 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 2430-170420
31 Mar 2423-163430
31 Dec 2317-164420
30 Sep 2315-148410
30 Jun 2313-144370
31 Mar 2311-137370
31 Dec 2210-129330
30 Sep 224-135290
30 Jun 2224-108290
31 Mar 2253-76230
31 Dec 2163-58210
30 Sep 211228210
30 Jun 21101-9210
31 Mar 2171-30200
31 Dec 2075-20190
30 Sep 2018-74180
30 Jun 2018-81170
31 Mar 2023-84160
31 Dec 198-97160
30 Sep 195-94160
30 Jun 1910-79160
31 Mar 195-69160
31 Dec 185-62160
30 Sep 188-52140
30 Jun 183-45130
31 Mar 1810-34110
31 Dec 1710-3090
30 Sep 1710-2780
30 Jun 1713-1960
31 Mar 1712-1550
31 Dec 1617-440
30 Sep 1618-440
30 Jun 1619-440
31 Mar 1618-640
31 Dec 1518-540
30 Sep 1517-230
30 Jun 1519030
31 Mar 1518130
31 Dec 1416020
31 Dec 135-620

質の高い収益: ANABは現在利益が出ていません。

利益率の向上: ANABは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: ANABは利益が出ておらず、過去 5 年間で損失は年間23%の割合で増加しています。

成長の加速: ANABの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ANABは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -2.3% ) と比較することは困難です。


株主資本利益率

高いROE: ANABは現在利益が出ていないため、自己資本利益率 ( -1721.99% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘